Therapeutic Response

PDGFRB rearrangements status confers therapeutic sensitivity to Imatinib in patients with Myeloproliferative Neoplasm.

Statements

Source and description
Glivec (imatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.